CLINICAL TRIAL SUMMARY

MDACC Study No:2009-0130 (clinicaltrials.gov NCT No: NCT00947856)
Title:Treatment with SGN-35 in patients with CD30-positive
hematologic malignancies who have previously participated in
an SGN-35 study
Principal Investigator:Michelle A. Fanale
Treatment Agent:SGN-35
Study Status:Terminated
Study Description:The goal of this clinical research study is to study the safety of SGN-35 (also
called brentuximab vedotin) for re-treating patients who have cancer that has
not responded to treatment or has come back after treatment. Researchers also
want to determine if re-treatment with SGN-35 can affect the tumor.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:SGN-35
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:Seattle Genetics, Inc.
Return Visit:Screening, Cycle 1, Days1, 2, 4, 8, 15 & 22. Cycle 2, Days 1, 8, 15, 16, 18,
22. End of Treatment and post End of Treatment.
Home Care:N/A


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michelle A. Fanale
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults